Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron has faced setbacks in the regulatory approval process, as evidenced by the CRL received for the Eylea HD pre-filled syringe. These challenges could potentially delay the launch of new ...

and Eylea HD with longer dosing intervals maintains a competitive profile with Roche's Vabysmo. Dupixent's solid launch in severe atopic dermatitis and asthma is extending to several other allergy ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Sales of the ophthalmology drug, Eylea, increased 4.7% to €815 million, driven by higher volumes. The launch of Eylea 8 mg, offering longer treatment intervals, provided a boost to sales ...

The TALON trial in the wet form of AMD will compare brolucizumab against Eylea (aflibercept ... and HARRIER – and the company is hoping to launch its new therapy before the end of the year ...

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimates of 63 cents. The company reported earnings of 77 cents ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...